NEW YORK, July 26 - Dutch pharmaceutical company Organon had agreed to renew and expand its subscription to Lexicon’s OmniBank library and DNA sequence database, Lexicon Genetics said Thursday.
Under the terms of the deal, Oragnon will have access to Lexicon’s tools through December 2002. In addition, Organon will also have access to Lexicon’s gene knockouts as well as to drug target validation data generated by Lexicon for specified targets.
In exchange, Organon will pay annual technology access fees and research funding of an undisclosed amount.
"We believe that Organon's decision to expand its target validation agreement with us is indicative of the value our partners receive by tapping Lexicon's technology and expertise to discover the in vivo functions of genes," Arthur Sands, CEO of Lexicon, said in a statement.
Driek Vergouwen, managing director of research and development at Organon, said that the deal would provide the company with valuable information about gene function.
"Lexicon's expertise in analyzing key mammalian phenotypic characteristics in gene knockouts will enable Organon to learn more about the functions of genes for the benefit of our drug discovery programs that focus on major human diseases," Vergouwen said.
Lexicon Genetics of The Woodlands, Texas, uses gene knockout technology to determine the functions of genes.